CN101993930A - In situ hybridization detection kit for bc1-2 genes, detection method and application thereof - Google Patents

Abstract

The invention relates to an in situ hybridization detection kit for bc1-2 genes. The in situ hybridization detection kit for the bc1-2 genes comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown as SEQ ID NO.1. The invention also provides an in situ hybridization detection method for the bc1-2 genes. In addition, the invention also provides application of the kit to preparation of medicaments for detecting cancers. The kit provided by the invention has the characteristics of high sensitivity and high specificity. The detection method of the invention is convenient and simple in operation and can be commonly used and popularized in hospitals above district level.

Description

A kind of hybridization in situ detection kit of bcl-2 gene and detection method thereof and application

[technical field]

The present invention relates to a kind of test kit, specifically about a kind of hybridization in situ detection kit and detection method and application of bcl-2 gene

[background technology]

Cancer also is malignant tumour, and tumour is meant body under the effect of various tumorigenesis factor, the cellular abnormality hyperplasia of local organization and the local lump that forms.The fundamental unit of cancerous lesion is a cancer cells.Have neonatal cell after the aging death of human body cell and replace it, keeping body function, human body overwhelming majority cells can hyperplasia, but this hyperplasia is limited, the hyperplasia of cancer cells then is endless, and this makes the intravital nutritive substance of patient by mass consumption.Simultaneously, cancer cells can also discharge multiple toxin, makes human body produce a series of symptoms, and it transfers to whole body growth and breeding everywhere during late period, cause at last that human body is become thin, unable, anaemia, poor appetite, heating and organ function are impaired etc., organ failure and death.

The data that provides according to domestic and international authoritative institution, the newly-increased number 1,600,000 of the annual cancer of China, death toll nearly 1,600,000, the patient 6,000,000, the annual newly-increased cancer patients 8,000,000 in the whole world, death toll is near 8,000,000, and the patient has 8,400 ten thousand people approximately, to double to the above number of the year two thousand twenty, this is one group of fearful numeral.And most cancer patientss have only very short lifetime, and up to the present the mankind also do not have this foul disease of beat cancer, and the key of how to accomplish to cure cancer is to accomplish the early diagnosis of gene level.

Cancer changes to the formation cancer before cancer, need several years, accomplish early detection, diagnosis, prognosis detection and the recurrence after the diagnosis and treatment, shift that to detect in early days be the key that reduces M ﹠ M.

The bcl-2 gene is the apoptosis suppressor from B cell follicular lymphoma rhexis point discovery, and it can make cell survival prolong, and the growth overbalance causes gathering of cell number, and the not obviously influence of the propagation of pair cell.The bcl-2 gene can suppress the apoptosis of multiple tissue, is studied in kinds of tumors as important apoptosis suppressor.Masuda etc. discover that renal plevis and transitional cell carcinoma of ureter bcl-2 positive rate raise with the tumour cell fractionated.High river equality discovers that urothelial tumor patient's recurrence frequency is higher than the negative patient on the bcl-2 male.4 years survival rate curves afterwards of bcl-2 positive patient obviously separate with the negative patient, and the bcl-2 immunostaining can be used as the prognostic indicator of medium-term and long-term survival.Find in the cancer of the stomach research in early days that bcl-2 expression level rising person is taken place easily to soak into and shifted, bcl-2-2psi is a kind of new bcl-2 that has shortened.The bcl-2 gene has very important clinical cancer to detect the index meaning.

Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics, so far, we might do more accurate early diagnosis on gene level, just can accomplish the early prediction diagnosis in canceration early stage or cancer cells formation (during mono-clonal).Adopt nucleic acid hybridization in situ technology for detection bcl-2 gene, the early diagnosis of the gene food of clinical all kinds cancer is had very important clinical meaning.

Hybridization in situ technique of the present invention (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark, under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized, with radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.

[summary of the invention]

The objective of the invention is provides a kind of purposes of hybridization in situ detection kit of bcl-2 gene at deficiency of the prior art.

One purpose more of the present invention is that a kind of hybridization in situ detection kit of bcl-2 gene is provided.

Another purpose of the present invention is that a kind of in situ hybridization detection method of bcl-2 gene is provided.

For achieving the above object, the technical scheme taked of the present invention is:

The application of a kind of hybridization in situ detection kit of bcl-2 gene in preparation detection Cancerous disease medicine, described test kit comprises hybridization probe, marker, described hybridization probe sequence such as SEQ ID:bcl-2 gene, sequence number NM_000633,6492bp, mRNA, 18q21.3 ", cds:494 ... 1213bp.

The RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.

Described marker is selected from radionuclide or non-radioactive marker.

Described radionuclide is selected from ³H, ³⁵S, ¹²⁵I or ³²A kind of among the P.

Described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.

Described non-radioactive marker is preferably from digoxin.

Described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.

For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:

A kind of hybridization in situ detection kit of bcl-2 gene comprises hybridization probe, marker, and wherein said hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.

For realizing above-mentioned the 3rd purpose, the technical scheme that the present invention takes is:

A kind of in situ hybridization detection method of bcl-2 gene, this method may further comprise the steps:

A, the hybridization probe in the test kit is contacted with RNA to be measured in the substrate, form hybridization complex;

The hybridization complex that b, detection a step obtain.

The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein Za Jiao concrete steps comprise:

Instrumentation:

1). sample to be measured is put into reactive tank;

2). instrument discards liquid automatically, adds Digestive system automatically;

3). instrument discards liquid automatically, and the back is fixing automatically;

4). instrument discards liquid automatically, automatically prehybridization (42 ℃);

5). instrument discards liquid automatically, cleans automatically;

6). instrument discards liquid automatically, automatically hybridization (42 ℃);

7). instrument discards liquid automatically, cleans automatically;

8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);

9). instrument discards liquid automatically, cleans colour developing automatically;

10). take out the mounting microscopy.

The invention has the advantages that:

1, test kit provided by the invention has characteristics highly sensitive, high specificity.

2, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.

3, clinical meaning of the present invention is that more early stage tracking detects cancer generation dynamic process, and the detection and the screening implement that are used for cancer prevention medical science.Diagnostic kit of the present invention is with other detects the oncofetal protein mark clinically, and the medical imaging inspection has remarkable difference.The present invention can detect the bcl-2 unconventionality expression on gene level, before medical imaging inspection and other inspection is not found occupancy cancer focus, before the cancer biochemical indicator does not produce unusually, also do not form before the lump, can accomplish the information acquisition of above abnormal gene expression early, give real prognosis early diagnosis of clinical cancer sufferer.So just might implement early diagnosis, early prevention, the early treatment of cancer, might from the source, thoroughly effect a radical cure the cancer foul disease.

[description of drawings]

Fig. 1 is a cancer patient bcl-2 overexpression picture in the embodiment of the invention.

Fig. 2 is that normal people bcl-2 expresses picture in the embodiment of the invention.

[embodiment]

Below in conjunction with accompanying drawing the specific embodiment of the invention is elaborated.

Embodiment 1

A kind of hybridization in situ detection kit of bcl-2 gene comprises hybridization probe, marker, synergistic agent, and wherein, described hybridization probe sequence is shown in SEQ ID NO.1.The hybridization probe digoxigenin labeled.Other liquid and sample in the test kit are composed as follows:

Digestive system 100 μ l/ manage 1 pipe/box colourless transparent liquid

Protection liquid 100 μ l/ pipe 1 pipe/box colourless transparent liquid

Prehybridization solution 1300 μ l/ manage 2 pipe/box colourless transparent liquids

Justice hybridization solution 10 μ l/ pipe 1 pipe/box colourless transparent liquid

Antisense hybridization solution 10 μ l/ manage 1 pipe/box colourless transparent liquid

Confining liquid 1000 μ l/ manage 1 pipe/box colourless transparent liquid

Alkaline phosphatase enzyme antibody 1 μ l/ manages 1 pipe/box colourless transparent liquid

Developer A 175 μ l/ manage 1 pipe/box yellow liquid

Developer B 320 μ l/ manage 1 pipe/box colourless transparent liquid

Light yellow or the colourless transparent liquid of damping fluid I 10x 90ml/ bottle 1 bottle/box

Light yellow or the colourless transparent liquid of damping fluid II 10x 80ml/ bottle 1 bottle/box

Light yellow or the colourless transparent liquid of damping fluid III 10x 20m/ bottle 3 bottle/boxes

Light yellow or the colourless transparent liquid of damping fluid IV 10x 90ml/ bottle 1 bottle/box

Stationary liquid 90ml/ bottle 1 bottle/box colourless transparent liquid

6/box of positive control sample

The explanation of mentioned reagent composition:＜all reagent are available from SIGMA)

1, Digestive system: the 20mg/ml Proteinase K, the 100mg Proteinase K adds DEPC-H ₂O 5ml;

2, the glycine of protection liquid: 0.2g adds 1 * damping fluid I of 1ml;

3, prehybridization solution: 1 * damping fluid II 7.5ml

50×D?3ml

10mg/ml?yest?t-RNA?750ul

11mg/ml?SALMON?TESTES?DNA 682ul

0.04M?EDTA?3ml

50％formamide?15ml

4, the bloking of confining liquid: 0.03g (buying from Roche Holding Ag) adds 1ml 1 * damping fluid III;

5,10x damping fluid I:(PH7.1-7.4)

NaCl?80g

Na ₂HPO ₄.12H ₂O 360g

KCl 2g

KH ₂PO ₄2g

Add tri-distilled water to 1l, and autoclaving;

6,10x damping fluid II:(PH7.0)

NaCl 175.3g

Trisodium Citrate 88.2g

Several of HCl

Add tri-distilled water to 1l, and autoclaving;

7, damping fluid III:(PH7.9)

Tris 121.1g

NaCl 87.66g

About HCl 60ml

Add tri-distilled water to 1l, and autoclaving;

8, damping fluid IV:

1M Tris-HCl (PH9.5): Tirs 121.1g adds about HCl 3ml, adds water 900ml, transfers PH to 9.5, adds water to 1l, and autoclaving;

1M NaCl:NaCl 58.44 adds water to 1l, and autoclaving;

0.5M MgCl ₂: 101.65g MgCl ₂.6H ₂O adds water to 1l, and autoclaving;

9, stationary liquid: Paraformaldehyde 96 40g adds 1 * damping fluid I to 1l, and heat (about 50-60 degree) is stirred to dissolving a little;

10, developer A:NBT 1g adds 70%DMF11.44ml;

11, developer B:BCIP 1g adds 100%DMF30ml.

Test kit of the present invention can many person-portions use or person-portion use.

Embodiment 2

A kind of bcl-2 gene hybridization in situ detection method and test kit thereof are used

One, sample disposal

1, with the centrifuge tube of 10ml, dress 4.5ml lymphocyte separation medium, again the 3ml anticoagulation is slowly added contain lymphocyte separation medium (blood: in centrifuge tube lymphocyte separation medium=1: 1.5), the centrifugal 10min of 2000r/min;

2, draw the middle layer white corpuscle to another centrifuge tube, in this pipe, add 1 * damping fluid I of about twice again, mixing, the centrifugal 10min of 1500g/min;

3, abandon supernatant. precipitation adds 1 * damping fluid I of about twice, mixing, the centrifugal 10min of 1500g/min;

4, abandon supernatant, and test tube mouth excess liquid is gone with the tissue suction.Again precipitation is made suspension, drop in push jack on the slide, seasoning.(hospital with good conditionsi can use the pelleter film-making.) 3ml blood, can do 4 slice, thin pieces;

5, with 40ml 4% stationary liquid, in glass jar, fixedly 30min uses 1 * damping fluid I to wash 5min again.Every cylinder can be put 16;

6, sample can be kept at-20 ℃, or continues to do experiment.

Two, reagent in the test kit is mixed with working concentration

1, with 10 * damping fluid I with tri-distilled water by being diluted to 1 * damping fluid I at 1: 10;

2, with 20 * damping fluid II with tri-distilled water by being diluted to 2 * damping fluid II at 1: 10;

By being diluted to 0.2 * damping fluid II at 1: 100; By being diluted to 0.1 * damping fluid II at 1: 200;

3, with 10 * damping fluid III with tri-distilled water by being diluted to 1 * damping fluid III at 1: 10;

4,10 * damping fluid IV with tri-distilled water by be diluted at 1: 10 * damping fluid IV (get 1#, 2#, each 10ml of 3#, add water to 100ml both can).

Three, experimental procedure:

1, gets two of every person's samples to be checked, two of (other two give over to check with) and positive control samples (test at every turn and do a pair of positive control);

2, in glass jar, add Digestive system (Digestive system 100ul adds 1 * damping fluid 199.9ml, is working concentration) 20ml.37 ℃ of water-bath preheatings 10 minutes.Put 16 slides into, handle 12min, use 1 * damping fluid I to wash 5min again for 37 ℃;

3, wash 10min with 0.2% protection liquid (protection liquid 1ml adds 1 * damping fluid I99ml and is working concentration), tri-distilled water is washed 5min, and above process is all carried out at glass jar.The slide seasoning;

4, slide is put into the box of preserving moisture, add prehybridization solution 20ul/ sheet. covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;

5, take out slide, discard cover glass, slide is put into glass jar, with 70%, 90%, 95% ethanol is respectively washed 2min, seasoning;

6, slide is put into the box of preserving moisture, two of every patient specimens, one adds just hybridization solution 20ul/ sheet, and another adds antisense hybridization solution 20ul/ sheet, covered, the lid box of tightly preserving moisture is placed on 16-24h in 42 ℃ of constant water bath box;

7, take out slide, discard cover glass, slide is put into glass jar

In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II

In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II

In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;

8, wash 30s with 1 * damping fluid III, take out slide, seasoning;

9, slide is put into the box of preserving moisture, add 0.5%l confining liquid (the 1ml confining liquid adds 5ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture, at room temperature act on 30min;

10, take out slide, III washes 30s with 1 * damping fluid, seasoning;

11, slide is put into the box of preserving moisture, add alkaline phosphatase enzyme antibody (adding 1.8ml 1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture and at room temperature act on 30min;

12, take out slide, wash 3 times, each 15min with 1 * damping fluid III;

13,1 * damping fluid IV washes 2min, adds developer (developer A73.3ul, developer B157.5ul are added among 30ml 1 * damping fluid IV, mixing), more than the room temperature lucifuge 12h;

14, wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.

Four, the result judges

100-300 cell of counting calculates the per-cent of catching the purple cell under light microscopic.

What the positive control sample added the antisense hybridization solution should catch purple more than 80%.

All add the negative internal reference of just hybridization solution should be colourless.

The cDNA of digoxigenin labeled, RNA and oligonucleotide probe, not only probe has a biotin labeling advantage, also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position), this hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized, method with immunohistochemical methods develops the color again, under light microscopic, observe existence and the location of mRNA,, judge the expression amount of goal gene according to painted cell count.

The inventive method is a nucleic acid hybridization in situ technology commonly used at present, and this method is used for determining by detecting the bcl-2 gene expression amount in the substrate cell whether cancer takes place.Clinical study shows that the bcl-2 gene is the specific gene of cancer, because the bcl-2 gene is not expressed in the normal people, expresses in cancer only, illustrates that cancer takes place, and is used for determining whether cancer takes place, or normal.Thereby obtain the diagnostic message of cancer.

The embodiment of the invention is sampled as: 5 of cancer patients, 5 of normal control groups.Take out all people's to be checked peripheral blood 3-5 milliliter (separation white corpuscle) and do in situ hybridization.The result represents that all cancer patients bcl-2 genes have overexpression, cell dyeing; Normal control group bcl-2 gene is not expressed the cell dye-free.Concrete outcome is asked for an interview Fig. 1 and Fig. 2.

Embodiment 3

Detect Cancerous disease and detect parallel laboratory test between the Cancerous disease with the bcl-2 kit gene with the CD147 kit gene.

Specificity, susceptibility, accuracy for each comfortable Cancerous disease of scientific evaluation said gene.We use the method for parallel test, detect the mRNA of said gene simultaneously, detection technique adopts the nucleic acid hybridization in situ technology, with same routine Cancerous disease peripheral blood of patients, detect bcl-2 gene and CD147 (CD147 gene-CD147 sequence number: AB085790 simultaneously, 972bp, cds:40 ... 849bp) the mRNA of gene (carrying out same procedure and step and reagent that the hybridization in situ technique of embodiment 1 and embodiment 2 is all adopted in nucleic acid hybridization in situ, immunohistochemical staining, mirror numeration down, report as a result etc.).Find the bcl-2 gene in the Cancerous disease patient expression amount than the expression amount height of CD147 gene same disease patient.The result shows that specificity, susceptibility, the accuracy of the diagnosis of bcl-2 gene pairs Cancerous disease are better than CD147 gene, and in situ hybridization genetic expression figure shows that bcl-2 expression of gene amount is 70%, and CD147 expression of gene amount is 50%.The index that test kit of the present invention is done in the Cancerous disease diagnosis has very important clinical meaning.

The above only is a preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.

SEQUENCE?LISTING

＜110〉Rui bends biotechnology (Shanghai) Co., Ltd.

＜120〉a kind of hybridization in situ detection kit of bc1-2 gene and detection method thereof and application

<130>/

<160>1

<170>PatentIn?version?3.3

<210>1

<211>6492

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>1

tttctgtgaa?gcagaagtct?gggaatcgat?ctggaaatcc?tcctaatttt?tactccctct 60

ccccgcgact?cctgattcat?tgggaagttt?caaatcagct?ataactggag?agtgctgaag 120

attgatggga?tcgttgcctt?atgcatttgt?tttggtttta?caaaaaggaa?acttgacaga 180

ggatcatgct?gtacttaaaa?aatacaacat?cacagaggaa?gtagactgat?attaacaata 240

cttactaata?ataacgtgcc?tcatgaaata?aagatccgaa?aggaattgga?ataaaaattt 300

cctgcatctc?atgccaaggg?ggaaacacca?gaatcaagtg?ttccgcgtga?ttgaagacac 360

cccctcgtcc?aagaatgcaa?agcacatcca?ataaaatagc?tggattataa?ctcctcttct 420

ttctctgggg?gccgtggggt?gggagctggg?gcgagaggtg?ccgttggccc?ccgttgcttt 480

tcctctggga?aggatggcgc?acgctgggag?aacagggtac?gataaccggg?agatagtgat 540

gaagtacatc?cattataagc?tgtcgcagag?gggctacgag?tgggatgcgg?gagatgtggg 600

cgccgcgccc?ccgggggccg?cccccgcacc?gggcatcttc?tcctcccagc?ccgggcacac 660

gccccatcca?gccgcatccc?gggacccggt?cgccaggacc?tcgccgctgc?agaccccggc 720

tgcccccggc?gccgccgcgg?ggcctgcgct?cagcccggtg?ccacctgtgg?tccacctgac 780

cctccgccag?gccggcgacg?acttctcccg?ccgctaccgc?cgcgacttcg?ccgagatgtc 840

cagccagctg?cacctgacgc?ccttcaccgc?gcggggacgc?tttgccacgg?tggtggagga 900

gctcttcagg?gacggggtga?actgggggag?gattgtggcc?ttctttgagt?tcggtggggt 960

catgtgtgtg?gagagcgtca?accgggagat?gtcgcccctg?gtggacaaca?tcgccctgtg 1020

gatgactgag?tacctgaacc?ggcacctgca?cacctggatc?caggataacg?gaggctggga 1080

tgcctttgtg?gaactgtacg?gccccagcat?gcggcctctg?tttgatttct?cctggctgtc 1140

tctgaagact?ctgctcagtt?tggccctggt?gggagcttgc?atcaccctgg?gtgcctatct 1200

gggccacaag?tgaagtcaac?atgcctgccc?caaacaaata?tgcaaaaggt?tcactaaagc 1260

agtagaaata?atatgcattg?tcagtgatgt?accatgaaac?aaagctgcag?gctgtttaag 1320

aaaaaataac?acacatataa?acatcacaca?cacagacaga?cacacacaca?cacaacaatt 1380

aacagtcttc?aggcaaaacg?tcgaatcagc?tatttactgc?caaagggaaa?tatcatttat 1440

tttttacatt?attaagaaaa?aaagatttat?ttatttaaga?cagtcccatc?aaaactcctg 1500

tctttggaaa?tccgaccact?aattgccaag?caccgcttcg?tgtggctcca?cctggatgtt 1560

ctgtgcctgt?aaacatagat?tcgctttcca?tgttgttggc?cggatcacca?tctgaagagc 1620

agacggatgg?aaaaaggacc?tgatcattgg?ggaagctggc?tttctggctg?ctggaggctg 1680

gggagaaggt?gttcattcac?ttgcatttct?ttgccctggg?ggctgtgata?ttaacagagg 1740

gagggttcct?gtggggggaa?gtccatgcct?ccctggcctg?aagaagagac?tctttgcata 1800

tgactcacat?gatgcatacc?tggtgggagg?aaaagagttg?ggaacttcag?atggacctag 1860

tacccactga?gatttccacg?ccgaaggaca?gcgatgggaa?aaatgccctt?aaatcatagg 1920

aaagtatttt?tttaagctac?caattgtgcc?gagaaaagca?ttttagcaat?ttatacaata 1980

tcatccagta?ccttaagccc?tgattgtgta?tattcatata?ttttggatac?gcacccccca 2040

actcccaata?ctggctctgt?ctgagtaaga?aacagaatcc?tctggaactt?gaggaagtga 2100

acatttcggt?gacttccgca?tcaggaaggc?tagagttacc?cagagcatca?ggccgccaca 2160

agtgcctgct?tttaggagac?cgaagtccgc?agaacctgcc?tgtgtcccag?cttggaggcc 2220

tggtcctgga?actgagccgg?ggccctcact?ggcctcctcc?agggatgatc?aacagggcag 2280

tgtggtctcc?gaatgtctgg?aagctgatgg?agctcagaat?tccactgtca?agaaagagca 2340

gtagaggggt?gtggctgggc?ctgtcaccct?ggggccctcc?aggtaggccc?gttttcacgt 2400

ggagcatggg?agccacgacc?cttcttaaga?catgtatcac?tgtagaggga?aggaacagag 2460

gccctgggcc?cttcctatca?gaaggacatg?gtgaaggctg?ggaacgtgag?gagaggcaat 2520

ggccacggcc?cattttggct?gtagcacatg?gcacgttggc?tgtgtggcct?tggcccacct 2580

gtgagtttaa?agcaaggctt?taaatgactt?tggagagggt?cacaaatcct?aaaagaagca 2640

ttgaagtgag?gtgtcatgga?ttaattgacc?cctgtctatg?gaattacatg?taaaacatta 2700

tcttgtcact?gtagtttggt?tttatttgaa?aacctgacaa?aaaaaaagtt?ccaggtgtgg 2760

aatatggggg?ttatctgtac?atcctggggc?attaaaaaaa?aaatcaatgg?tggggaacta 2820

taaagaagta?acaaaagaag?tgacatcttc?agcaaataaa?ctaggaaatt?tttttttctt 2880

ccagtttaga?atcagccttg?aaacattgat?ggaataactc?tgtggcatta?ttgcattata 2940

taccatttat?ctgtattaac?tttggaatgt?actctgttca?atgtttaatg?ctgtggttga 3000

tatttcgaaa?gctgctttaa?aaaaatacat?gcatctcagc?gtttttttgt?ttttaattgt 3060

atttagttat?ggcctataca?ctatttgtga?gcaaaggtga?tcgttttctg?tttgagattt 3120

ttatctcttg?attcttcaaa?agcattctga?gaaggtgaga?taagccctga?gtctcagcta 3180

cctaagaaaa?acctggatgt?cactggccac?tgaggagctt?tgtttcaacc?aagtcatgtg 3240

catttccacg?tcaacagaat?tgtttattgt?gacagttata?tctgttgtcc?ctttgacctt 3300

gtttcttgaa?ggtttcctcg?tccctgggca?attccgcatt?taattcatgg?tattcaggat 3360

tacatgcatg?tttggttaaa?cccatgagat?tcattcagtt?aaaaatccag?atggcaaatg 3420

accagcagat?tcaaatctat?ggtggtttga?cctttagaga?gttgctttac?gtggcctgtt 3480

tcaacacaga?cccacccaga?gccctcctgc?cctccttccg?cgggggcttt?ctcatggctg 3540

tccttcaggg?tcttcctgaa?atgcagtggt?gcttacgctc?caccaagaaa?gcaggaaacc 3600

tgtggtatga?agccagacct?ccccggcggg?cctcagggaa?cagaatgatc?agacctttga 3660

atgattctaa?tttttaagca?aaatattatt?ttatgaaagg?tttacattgt?caaagtgatg 3720

aatatggaat?atccaatcct?gtgctgctat?cctgccaaaa?tcattttaat?ggagtcagtt 3780

tgcagtatgc?tccacgtggt?aagatcctcc?aagctgcttt?agaagtaaca?atgaagaacg 3840

tggacgtttt?taatataaag?cctgttttgt?cttttgttgt?tgttcaaacg?ggattcacag 3900

agtatttgaa?aaatgtatat?atattaagag?gtcacggggg?ctaattgctg?gctggctgcc 3960

ttttgctgtg?gggttttgtt?acctggtttt?aataacagta?aatgtgccca?gcctcttggc 4020

cccagaactg?tacagtattg?tggctgcact?tgctctaaga?gtagttgatg?ttgcattttc 4080

cttattgtta?aaaacatgtt?agaagcaatg?aatgtatata?aaagcctcaa?ctagtcattt 4140

ttttctcctc?ttcttttttt?tcattatatc?taattatttt?gcagttgggc?aacagagaac 4200

catccctatt?ttgtattgaa?gagggattca?catctgcatc?ttaactgctc?tttatgaatg 4260

aaaaaacagt?cctctgtatg?tactcctctt?tacactggcc?agggtcagag?ttaaatagag 4320

tatatgcact?ttccaaattg?gggacaaggg?ctctaaaaaa?agccccaaaa?ggagaagaac 4380

atctgagaac?ctcctcggcc?ctcccagtcc?ctcgctgcac?aaatactccg?caagagaggc 4440

cagaatgaca?gctgacaggg?tctatggcca?tcgggtcgtc?tccgaagatt?tggcaggggc 4500

agaaaactct?ggcaggctta?agatttggaa?taaagtcaca?gaattaagga?agcacctcaa 4560

tttagttcaa?acaagacgcc?aacattctct?ccacagctca?cttacctctc?tgtgttcaga 4620

tgtggccttc?catttatatg?tgatctttgt?tttattagta?aatgcttatc?atctaaagat 4680

gtagctctgg?cccagtggga?aaaattagga?agtgattata?aatcgagagg?agttataata 4740

atcaagatta?aatgtaaata?atcagggcaa?tcccaacaca?tgtctagctt?tcacctccag 4800

gatctattga?gtgaacagaa?ttgcaaatag?tctctatttg?taattgaact?tatcctaaaa 4860

caaatagttt?ataaatgtga?acttaaactc?taattaattc?caactgtact?tttaaggcag 4920

tggctgtttt?tagactttct?tatcacttat?agttagtaat?gtacacctac?tctatcagag 4980

aaaaacagga?aaggctcgaa?atacaagcca?ttctaaggaa?attagggagt?cagttgaaat 5040

tctattctga?tcttattctg?tggtgtcttt?tgcagcccag?acaaatgtgg?ttacacactt 5100

tttaagaaat?acaattctac?attgtcaagc?ttatgaaggt?tccaatcaga?tctttattgt 5160

tattcaattt?ggatctttca?gggatttttt?ttttaaatta?ttatgggaca?aaggacattt 5220

gttggagggg?tgggagggag?gaagaatttt?taaatgtaaa?acattcccaa?gtttggatca 5280

gggagttgga?agttttcaga?ataaccagaa?ctaagggtat?gaaggacctg?tattggggtc 5340

gatgtgatgc?ctctgcgaag?aaccttgtgt?gacaaatgag?aaacattttg?aagtttgtgg 5400

tacgaccttt?agattccaga?gacatcagca?tggctcaaag?tgcagctccg?tttggcagtg 5460

caatggtata?aatttcaagc?tggatatgtc?taatgggtat?ttaaacaata?aatgtgcagt 5520

tttaactaac?aggatattta?atgacaacct?tctggttggt?agggacatct?gtttctaaat 5580

gtttattatg?tacaatacag?aaaaaaattt?tataaaatta?agcaatgtga?aactgaattg 5640

gagagtgata?atacaagtcc?tttagtctta?cccagtgaat?cattctgttc?catgtctttg 5700

gacaaccatg?accttggaca?atcatgaaat?atgcatctca?ctggatgcaa?agaaaatcag 5760

atggagcatg?aatggtactg?taccggttca?tctggactgc?cccagaaaaa?taacttcaag 5820

caaacatcct?atcaacaaca?aggttgttct?gcataccaag?ctgagcacag?aagatgggaa 5880

cactggtgga?ggatggaaag?gctcgctcaa?tcaagaaaat?tctgagacta?ttaataaata 5940

agactgtagt?gtagatactg?agtaaatcca?tgcacctaaa?ccttttggaa?aatctgccgt 6000

gggccctcca?gatagctcat?ttcattaagt?ttttccctcc?aaggtagaat?ttgcaagagt 6060

gacagtggat?tgcatttctt?ttggggaagc?tttcttttgg?tggttttgtt?tattatacct 6120

tcttaagttt?tcaaccaagg?tttgcttttg?ttttgagtta?ctggggttat?ttttgtttta 6180

aataaaaata?agtgtacaat?aagtgttttt?gtattgaaag?cttttgttat?caagattttc 6240

atacttttac?cttccatggc?tctttttaag?attgatactt?ttaagaggtg?gctgatattc 6300

tgcaacactg?tacacataaa?aaatacggta?aggatacttt?acatggttaa?ggtaaagtaa 6360

gtctccagtt?ggccaccatt?agctataatg?gcactttgtt?tgtgttgttg?gaaaaagtca 6420

cattgccatt?aaactttcct?tgtctgtcta?gttaatattg?tgaagaaaaa?taaagtacag 6480

tgtgagatac?tg 6492

Claims (10)

1. the application of the hybridization in situ detection kit of a bcl-2 gene in preparation detection Cancerous disease medicine, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.

2. application according to claim 1 is characterized in that: the RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.

3. application according to claim 1 and 2 is characterized in that: described marker is selected from radionuclide or non-radioactive marker.

4. application according to claim 3 is characterized in that: described radionuclide is selected from ³H, ³⁵S, ¹²⁵I or ³²A kind of among the P.

5. application according to claim 3 is characterized in that: described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.

6. application according to claim 5 is characterized in that: described non-radioactive marker is preferably from digoxin.

7. application according to claim 1 and 2 is characterized in that: described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.

8. the hybridization in situ detection kit of a bcl-2 gene comprises hybridization probe, marker, it is characterized in that, described hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.

9. the in situ hybridization detection method of a bcl-2 gene is characterized in that, this method may further comprise the steps:

A, the hybridization probe in the described test kit of claim 8 is contacted with RNA to be measured in the substrate, form hybridization complex;

The hybridization complex that b, detection a step obtain.

10. detection method according to claim 9 is characterized in that: the condition that forms hybridization complex in a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour, and described substrate is selected blood cell sample or histocyte sample for use.

Images